Zhang Lin, Mao Lihong, Xu Junxiu
Department of Clinical Laboratory, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Oncotarget. 2016 Jan 19;7(3):2455-61. doi: 10.18632/oncotarget.6289.
Some studies have demonstrated that transforming growth factor (TGF)-β polymorphisms may have an important role in the pathological process of graft-versus-host disease (GVHD). However, the results are not consistent. Thus, we performed a meta-analysis. Online databases were searched to obtain relevant articles published up until May 2015. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of associations. Donors (OR=0.56; 95%CI, 0.32-0.98; P=0.04) and recipients (OR=0.73; 95%CI, 0.63-0.85; P<0.0001) with TGF-β1 rs1800469 polymorphism showed decreased GVHD risk, respectively. Donors with TGF-β1 rs1800470 polymorphism were also observed to have lower GVHD risk (OR=0.65; 95%CI, 0.46-0.94; P=0.02). However, TGF-β1 rs1800470 polymorphism in recipients was not associated with GVHD risk (OR=1.28; 95%CI, 0.81-2.01; P=0.29). No significant heterogeneity was found in the meta-analysis. This meta-analysis suggests that donors or recipients with TGF-β1 rs1800469 polymorphism and donors with TGF-β1 rs1800470 polymorphism might be associated with reduced GVHD risk.
一些研究表明，转化生长因子（TGF）-β基因多态性可能在移植物抗宿主病（GVHD）的病理过程中起重要作用。然而，结果并不一致。因此，我们进行了一项荟萃分析。检索在线数据库以获取截至2015年5月发表的相关文章。采用比值比（OR）及95%置信区间（CI）评估关联强度。携带TGF-β1 rs1800469基因多态性的供者（OR=0.56；95%CI，0.32-0.98；P=0.04）和受者（OR=0.73；95%CI，0.63-0.85；P<0.0001）发生GVHD的风险分别降低。携带TGF-β1 rs1800470基因多态性的供者发生GVHD的风险也较低（OR=0.65；95%CI，0.46-0.94；P=0.02）。然而，受者中TGF-β1 rs1800470基因多态性与GVHD风险无关（OR=1.28；95%CI，0.81-2.01；P=0.29）。荟萃分析未发现显著异质性。该荟萃分析表明，携带TGF-β1 rs1800469基因多态性的供者或受者以及携带TGF-β1 rs1800470基因多态性的供者可能与GVHD风险降低有关。
